美国血液学学会第五十七次会议上的报告综述 - 中国病毒学论坛|我们一直在坚持！

The 57th American Society ofHaematology (ASH) meeting held in Orlando, FL was certainly the year whenmyeloma management changed for good, with a plethora of newly Food and DrugAdministration (FDA)-approved drugs showing impressive outcome improvements andthe introduction of new techniques for disease monitoring. Also, chimericantigen receptor (CAR) T cells continued their triumphal march, consolidatingtheir success in lymphoma and chronic lymhocytic leukaemia (CLL) and venturinginto new fields such as again multiple myeloma. Some experimental drugs showedlong-awaited results (midostaurin in FLT3-mutated acute myeloid leukaemia(AML)) and some brand new drugs showed promising results in the clinic afterextensive preclinical studies, such as those targeting new epigenetic factors(histone methyltransferases) and apoptosis.

57届美国血液学年会在奥兰多举行，随着大量新的食品和药物管理局（FDA）批准的药物表现出令人印象深刻的结果、改进和疾病监测新技术的引进，本年是骨髓瘤管理变好的一年。另外，嵌合抗原受体（CAR）的T细胞也继续变现出他们的成功，除了巩固其在淋巴瘤和慢性淋巴细胞白血病（CLL）的效果，也成功进入了多发性骨髓瘤等新领域。此外，一些实验性药物显示了期待已久的结果（如米哚妥林对FLT3突变的急性髓细胞性白血病（AML）），在临床上经过广泛的临床前研究，一些全新的药物显示出可喜的成果，例如针对新的表观遗传因素（组蛋白甲基转移酶）和细胞凋亡的药物。